Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review

References

• MollJMWrightVPsoriatic arthritisSemin Arthritis Rheum1973355784581554
   PubMedGoogle Scholar
• GladmanDDAntoniCMeasePCleggDONashPPsoriatic arthritis: epidemiology, clinical features, course, and outcomeAnn Rheum Dis200564Suppl 2ii14ii1715708927
   PubMed Web of Science ®Google Scholar
• McDonoughEAyearstREderLDepression and anxiety in psoriatic disease: prevalence and associated factorsJ Rheumatol20144188789624692521
   PubMed Web of Science ®Google Scholar
• OgdieAYuYHaynesKRisk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort studyAnn Rheum Dis201574232633225351522
   PubMed Web of Science ®Google Scholar
• ShbeebMUramotoKMGibsonLEO’FallonWMGabrielSEThe epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991J Rheumatol2000271247125010813295
   PubMed Web of Science ®Google Scholar
• OgdieALanganSLoveTPrevalence and treatment patterns of psoriatic arthritis in the UKRheumatology20135256857523221331
   PubMed Web of Science ®Google Scholar
• MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol20085882685018423260
   PubMed Web of Science ®Google Scholar
• RitchlinCTKavanaughAGladmanDDTreatment recommendations for psoriatic arthritisAnn Rheum Dis2009681387139418952643
   PubMed Web of Science ®Google Scholar
• SIGNSIGN Guideline 121: Diagnosis and Management of Psoriasis and Psoriatic Arthritis in Adults2010 Available from: http://sign.ac.uk/guidelines/fulltext/121/contents.htmlAccessed January 19, 2015
   Google Scholar
• NICE Technology AppraisalsEtanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis2010 Available from: https://www.nice.org.uk/guidance/ta199Accessed January 19, 2015
   Google Scholar
• GossecLSmolenJSGaujoux-VialaCEuropean League Against RheumatismEuropean league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapiesAnn Rheum Dis20127141221953336
   PubMed Web of Science ®Google Scholar
• CoatesLCTillettWChandlerDThe 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologicsRheumatology2013521754175723887065
   PubMed Web of Science ®Google Scholar
• JonesGCrottyMBrooksPPsoriatic arthritis: a quantitative overview of therapeutic options. The psoriatic arthritis meta-analysis study groupBr J Rheumatol19973695999117186
   PubMedGoogle Scholar
• WoolacottNBravo VergelYHawkinsNEtanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluationHealth Technol Assess2006101239
   PubMed Web of Science ®Google Scholar
• KavanaughAFRitchlinCTGRAPPA Treatment Guideline CommitteeSystematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelinesJ Rheumatol2006331417142116724373
   PubMed Web of Science ®Google Scholar
• SorianoERMcHughNJTherapies for peripheral joint disease in psoriatic arthritis. A systematic reviewJ Rheumatol2006331422143016724372
   PubMed Web of Science ®Google Scholar
• WoolacottNFKhadjesariZCBruceINRiemsmaRPEtanercept and infliximab for the treatment of psoriatic arthritis: a systematic reviewClin Exp Rheumatol20062458759317181932
   PubMed Web of Science ®Google Scholar
• RavindranVScottDLChoyEHA systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritisAnn Rheum Dis20086785585917827183
   PubMed Web of Science ®Google Scholar
• LamelSAMyerKAYounesNZhouJAMaibachHMaibachHIPlacebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatmentArch Dermatol Res201230470771722843024
   PubMed Web of Science ®Google Scholar
• PeredaCANishishinyaMBMartínez LópezJACarmonaLEvidence-Based Working Group of the Spanish Society of RheumatologyEfficacy and safety of DMARDs in psoriatic arthritis: a systematic reviewClin Exp Rheumatol20123028228922339882
   PubMed Web of Science ®Google Scholar
• AshZGaujoux-VialaCGossecLA systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritisAnn Rheum Dis20127131932621803753
   PubMed Web of Science ®Google Scholar
• Acosta FelquerMLCoatesLCSorianoERDrug therapies for peripheral joint disease in psoriatic arthritis: a systematic reviewJ Rheumatol2014412277228525362711
   PubMed Web of Science ®Google Scholar
• CoatesLCKavanaughARitchlinCTGRAPPA Treatment Guideline CommitteeSystematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPAJ Rheumatol2014412273227625362710
   PubMed Web of Science ®Google Scholar
• CawsonMRMitchellSAKnightCSystematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritisBMC Musculoskelet Disord2014152624444034
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med20096e100009719621072
   PubMed Web of Science ®Google Scholar
• TaylorWGladmanDHelliwellPCASPAR Study GroupClassification criteria for psoriatic arthritis: development of new criteria from a large international studyArthritis Rheum2006542665267316871531
   PubMed Web of Science ®Google Scholar
• ViswanathanMAnsariMTBerkmanNDAssessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care InterventionsMethods Guide for Effectiveness and Comparative Effectiveness ReviewsRockville, MD2008 Available from: http://www.ncbi.nlm.nih.gov/books/NBK91433/?report=printableAccessed January 19, 2015
   Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials198671771883802833
   PubMed Web of Science ®Google Scholar
• HardyRJThompsonSGDetecting and describing heterogeneity in meta-analysisStat Med1998178418569595615
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ200332755756012958120
   PubMed Web of Science ®Google Scholar
• WillkensRFWilliamsHJWardJRRandomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritisArthritis Rheum1984273763816712754
   PubMed Web of Science ®Google Scholar
• PalitJHillJCapellHAA multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritisBr J Rheumatol1990292802832116206
   PubMedGoogle Scholar
• FarrMKitasGDWaterhouseLJubbRFelix-DaviesDBaconPASulphasalazine in psoriatic arthritis: a double-blind placebo-controlled studyBr J Rheumatol19902946491968355
   PubMedGoogle Scholar
• FraserSMHopkinsRHunterJANeumannVCapellHABirdHASulphasalazine in the management of psoriatic arthritisBr J Rheumatol1993329239258104656
   PubMedGoogle Scholar
• CleggDORedaDJMejiasEComparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative StudyArthritis Rheum199639201320208961906
   PubMed Web of Science ®Google Scholar
• CombeBGoupillePKuntzJLTebibJLiotéFBregeonCSulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled studyBr J Rheumatol1996356646688670601
   PubMedGoogle Scholar
• SalvaraniCMacchioniPOlivieriIA comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritisJ Rheumatol2001282274228211669169
   PubMed Web of Science ®Google Scholar
• KaltwasserJPNashPGladmanDTreatment of Psoriatic Arthritis Study GroupEfficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialArthritis Rheum2004501939195015188371
   PubMed Web of Science ®Google Scholar
• FraserADvan KuijkAWWesthovensRA randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritisAnn Rheum Dis20056485986415528283
   PubMed Web of Science ®Google Scholar
• ScarpaRPelusoRAttenoMThe effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexateClin Rheumatol20082782382618030515
   PubMed Web of Science ®Google Scholar
• KingsleyGHKowalczykATaylorHA randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology2012511368137722344575
   PubMed Web of Science ®Google Scholar
• SchettGWollenhauptJPappKOral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled studyArthritis Rheum2012643156316722806399
   PubMed Web of Science ®Google Scholar
• KavanaughAMeasePJGomez-ReinoJJTreatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorAnn Rheum Dis2014731020102624595547
   PubMed Web of Science ®Google Scholar
• MeasePJGoffeBSMetzJVanderStoepAFinckBBurgeDJEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet200035638539010972371
   PubMed Web of Science ®Google Scholar
• MeasePJKivitzAJBurchFXEtanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progressionArthritis Rheum2004502264227215248226
   PubMed Web of Science ®Google Scholar
• AntoniCEKavanaughAKirkhamBSustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis Rheum2005521227123615818699
   PubMed Web of Science ®Google Scholar
• AntoniCKruegerGGde VlamKIMPACT 2 Trial InvestigatorsInfliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialAnn Rheum Dis2005641150115715677701
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDRitchlinCTAdalimumab Effectiveness in Psoriatic Arthritis Trial Study GroupAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialArthritis Rheum2005523279328916200601
   PubMed Web of Science ®Google Scholar
• GenoveseMCMeasePJThomsonGTSafety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapyJ Rheumatol2007341040105017444593
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialLancet200937363364019217154
   PubMed Web of Science ®Google Scholar
• KavanaughAMcInnesIMeasePGolimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthritis Rheum20096097698619333944
   PubMed Web of Science ®Google Scholar
• MeasePGenoveseMCGladsteinGAbatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialArthritis Rheum20116393994821128258
   PubMed Web of Science ®Google Scholar
• BaranauskaiteARaffayováHKungurovNVRESPOND investigatorsInfliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND studyAnn Rheum Dis20127154154821994233
   PubMed Web of Science ®Google Scholar
• McInnesIBKavanaughAGottliebABPSUMMIT 1 Study GroupEfficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet201338278078923769296
   PubMed Web of Science ®Google Scholar
• McInnesIBSieperJBraunJEfficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trialAnn Rheum Dis20147334935623361084
   PubMed Web of Science ®Google Scholar
• MeasePJFleischmannRDeodharAAEffect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)Ann Rheum Dis201473485523942868
   PubMed Web of Science ®Google Scholar
• MeasePJGenoveseMCGreenwaldMWBrodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritisN Engl J Med20143702295230624918373
   PubMed Web of Science ®Google Scholar
• RitchlinCRahmanPKavanaughAPSUMMIT 2 Study GroupEfficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialAnn Rheum Dis20147399099924482301
   PubMed Web of Science ®Google Scholar
• CutoloMMyersonGEFleischmannRMLong-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2)Arthritis Rheum201365S346S347
   Google Scholar
• EdwardsCJBlancoFJCrowleyJHuCStevensRMBirbaraCALong-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3)Arthritis Rheum201365S132
   Google Scholar
• WellsAFEdwardsCJAdebajoAOApremilast in the treatment of DMARD-naive psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4)Arthritis Rheum201365S3320S3321
   Google Scholar
• MeasePMcInnesIBKirkhamBSecukinumab, a Human anti-interleukin-17A monoclonal antibodyArthritis Rheum201466S423S424
   Web of Science ®Google Scholar
• McInnesIBMeasePJKirkhamBSecukinumab, a human anti-interleukin-17A monoclonal Antibody, improves active psoriatic arthritis: 24 week efficacy and safety data from a phase 3 randomised multicentre, double-blind, placebo-controlled study using subcutaneousArthritis Rheum2014662539
   Web of Science ®Google Scholar
• MeasePGottliebABBermanAA phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakizumab, an anti-IL-6 monoclonal antibody, in adults with active psoriatic arthritisArthritis Rheum201466S423
   Web of Science ®Google Scholar
• StrandVMeasePJMcInnesIBSecukinumab, an anti-interleukin-17A monoclonal antibody, improves physical function, quality of life and work productivity in patients with active psoriatic arthritis: results from a phase 3, randomized, controlled trialArthritis Rheum201466S240S241
   Web of Science ®Google Scholar
• DonahueKEGartlehnerGJonasDESystematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritisAnn Intern Med200814812413418025440
   PubMed Web of Science ®Google Scholar
• van den BergRBaraliakosXBraunJvan der HeijdeDFirst update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitisRheumatology2012511388139622513148
   PubMed Web of Science ®Google Scholar
• KavanaughASanzLPGottliebABLong term improvements in physical function are associated with improvements in dactylitis, enthesitis, tender and swollen joint counts, and psoriasis skin involvement: results from a phase 3 study of ustekinumab in psoriatic arthritis patientsArthritis Rheum201466S688
   Web of Science ®Google Scholar
• KavanaughASanzLPGottliebABEfficacy and safety of ustekinumab in psoriatic arthritis patients with spondylitis and peripheral joint involvement: results from a phase 3 multicenter double-blind placebo-controlled studyArthritis Rheum201466S234
   Web of Science ®Google Scholar
• RitchlinCRahmanPSanzLPTreatment effect of ustekinumab on fatigue in patients with psoriatic arthritis: results from PSUMMIT 2Clin Exp Rheumatol201432824
   Google Scholar
• KavanaughAMcInnesIBRitchlinCTIntegrated safety of ustekinumab in psoriatic arthritis: 2 year follow-up from the psoriatic arthritis clinical development programArthritis Rheum201466S686S687
   Web of Science ®Google Scholar
• NICE Technology Appraisals TA313Ustekinumab for Treating Active Psoriatic Arthritis2014 Available from: https://www.nice.org.uk/guidance/ta313Accessed May 20, 2014
   Google Scholar
• van der HeijdeDRobertBMLandewéRBSecukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled studyArthritis Rheum201466S424S425
   Web of Science ®Google Scholar
• HartBLundhABeroLEffect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analysesBMJ2012344d720222214754
   PubMed Web of Science ®Google Scholar
• CoatesLCNavarro-CoyNBrownSRThe TICOPA protocol (tight control of psoriatic arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritisBMC Musculoskelet Disord20131410123517506
   PubMed Web of Science ®Google Scholar
• GottliebABArmstrongAWPsoriasis outcome measures: a report from the GRAPPA 2012 annual meetingJ Rheumatol2013401428143323908539
   PubMed Web of Science ®Google Scholar